Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 16/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.61 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532579 | 1.00 | CETP (0.61) | CETPNR1I2PTGDR2KCNH2 | |
| SCHEMBL14874761 | 1.00 | CETP (0.61) | CETPNR1I2PTGDR2KCNH2 | |
| SCHEMBL3577311 | 1.00 | CETP (0.61) | CETPNR1I2PTGDR2KCNH2 | |
| SCHEMBL531912 | 1.00 | CETP (0.61) | CETPNR1I2PTGDR2KCNH2 | |
| SCHEMBL12696971 | 0.94 | CETP (0.55) | CETPNR1I2PTGDR2KCNH2 | |
| SCHEMBL1529173 | 0.93 | CETP (0.54) | CETPNR1I2PTGDR2KCNH2 | |
| SCHEMBL4307662 | 0.90 | CETP (0.55) | CETPNR1I2PTGDR2KCNH2 | |
| SCHEMBL1529174 | 0.89 | CETP (0.50) | CETPNR1I2PTGDR2 | |
| SCHEMBL531641 | 0.88 | CETP (0.51) | CETPNR1I2 | |
| SCHEMBL531640 | 0.88 | CETP (0.51) | CETPNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029560-B1 | 1,3-OXAZOLIDIN-2-ONE DERIVATIVES USEEFUL AS CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| US-7781426-B2 | cholesterol ester transfer protein (CETP) inhibitors such as (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[2-(3,3-dimethylpiperidin-1-yl)-5-(trifluoromethyl)benzyl]-4-methyl-1,3-oxazolidin-2-one, useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis | MERCK SHARP & DOHME CORP. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20090075979-A1 | CETP Inhibitors | MERCK SHARP & DOHME LLC | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075979-A1 | CETP Inhibitors | CETP, APOB, MTTP | CETP 1/4885NR1I2 56/4885PTGDR2 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.